Screener
Artiva Biotherapeutics, Inc. ARTV Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
FAQ
- What is Artiva Biotherapeutics, Inc.'s total equity?
- Artiva Biotherapeutics, Inc. (ARTV) reported total equity of $347.5M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s total equity changed year-over-year?
- Artiva Biotherapeutics, Inc.'s total equity increased by 133.2% year-over-year, from $149.04M to $347.5M.
- What is the long-term trend for Artiva Biotherapeutics, Inc.'s total equity?
- Over 3 years (2022 to 2025), Artiva Biotherapeutics, Inc.'s total equity has grown at a -7.9% compound annual growth rate (CAGR), from -$140.7M to $109.97M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Artiva Biotherapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude